Barclays analyst says outcome is worst for Amgen
A Barclays analyst, Emily Field, said the Novartis heart-disease drug announcement was “the worst possible outcome for Amgen,” adding it cast doubt on one of Amgen’s major drugs.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.